newsfilter
← Latest News
GlobeNewswire·

Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update

Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc.